Q2 EPS Estimates for Globus Medical Raised by Roth Capital

Globus Medical, Inc. (NYSE:GMED - Free Report) - Roth Capital increased their Q2 2025 EPS estimates for shares of Globus Medical in a report issued on Monday, July 21st. Roth Capital analyst J. Wittes now anticipates that the medical device company will earn $0.76 per share for the quarter, up from their previous forecast of $0.75. The consensus estimate for Globus Medical's current full-year earnings is $3.44 per share. Roth Capital also issued estimates for Globus Medical's Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $3.15 EPS, Q2 2026 earnings at $0.91 EPS, FY2026 earnings at $3.70 EPS and FY2027 earnings at $3.97 EPS.

Several other equities analysts have also recently issued reports on the stock. Morgan Stanley decreased their target price on shares of Globus Medical from $75.00 to $68.00 and set an "overweight" rating for the company in a research note on Tuesday, July 15th. Piper Sandler decreased their target price on shares of Globus Medical from $100.00 to $80.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Needham & Company LLC reiterated a "hold" rating on shares of Globus Medical in a research note on Monday, July 21st. BTIG Research reiterated a "neutral" rating on shares of Globus Medical in a research note on Tuesday, May 27th. Finally, Barclays reiterated an "overweight" rating on shares of Globus Medical in a research note on Tuesday, June 10th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Globus Medical presently has an average rating of "Moderate Buy" and an average price target of $90.09.

Globus Medical Stock Performance

Shares of GMED traded up $1.16 during trading hours on Thursday, hitting $54.45. The stock had a trading volume of 1,399,239 shares, compared to its average volume of 1,640,347. The firm has a 50-day moving average price of $58.19 and a 200 day moving average price of $70.91. Globus Medical has a fifty-two week low of $51.87 and a fifty-two week high of $94.93. The firm has a market capitalization of $7.37 billion, a price-to-earnings ratio of 40.63, a PEG ratio of 1.59 and a beta of 1.19.

Globus Medical (NYSE:GMED - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical device company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.06). The business had revenue of $598.12 million during the quarter, compared to analysts' expectations of $629.74 million. Globus Medical had a net margin of 7.39% and a return on equity of 10.52%. The firm's revenue was down 1.4% on a year-over-year basis. During the same period last year, the company earned $0.72 earnings per share.

Hedge Funds Weigh In On Globus Medical

A number of large investors have recently added to or reduced their stakes in GMED. Commonwealth Equity Services LLC grew its holdings in shares of Globus Medical by 11.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 7,787 shares of the medical device company's stock worth $644,000 after buying an additional 831 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Globus Medical by 3.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,920 shares of the medical device company's stock worth $572,000 after buying an additional 200 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Globus Medical by 255.9% during the fourth quarter. American Century Companies Inc. now owns 103,833 shares of the medical device company's stock worth $8,588,000 after buying an additional 74,659 shares in the last quarter. Sei Investments Co. grew its holdings in shares of Globus Medical by 4.9% during the fourth quarter. Sei Investments Co. now owns 96,775 shares of the medical device company's stock worth $8,004,000 after buying an additional 4,505 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Globus Medical during the fourth quarter worth $1,900,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical announced that its board has initiated a share buyback program on Thursday, May 15th that allows the company to buyback $500.00 million in shares. This buyback authorization allows the medical device company to reacquire up to 6.3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's leadership believes its shares are undervalued.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.